Seltorexant
- Generic Name
- Seltorexant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22FN7O
- CAS Number
- 1452539-75-1
- Unique Ingredient Identifier
- AIS8N3O50B
- Background
Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 757
- Registration Number
- NCT04513912
- Locations
- π¨πΏ
A Shine S R O, Plzen, Czechia
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈSW Biomedical Research LLC, Tucson, Arizona, United States
A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT03494907
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 107
- Registration Number
- NCT03321526
- Locations
- πΊπΈ
Hapworth Psychiatric Medical PLLC, New York, New York, United States
πΊπΈSuburban Clinical Research Group, Inc, Bolingbrook, Illinois, United States
πΊπΈEricksen Research and Development, Clinton, Utah, United States
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 24
- Registration Number
- NCT03249402
- Locations
- π§πͺ
SGS Life Science Services, Antwerpen, Belgium
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 287
- Registration Number
- NCT03227224
- Locations
- π·πΊ
Engels psychiatric hospital, Saratov Region, Russian Federation
π·πΊClinical Psychiatry Hospital n.a. N.N. Solodovnikov, Omsk, Russian Federation
π·πΊCity Psychiatric Hospital of St. Nikolay Chudotvorets, Saint-Petersburg, Russian Federation
A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT02661893
A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02617810
Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 36
- Registration Number
- NCT02578472
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 48
- Registration Number
- NCT02476058
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02475161
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.